Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 13/20 | 0.68 |
| ▸ | GAA | P10253 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4495467 | 0.99 | NR1H4 (0.67) | NR1H4GAAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4498524 | 0.84 | GAA (0.63) | NR1H4GAAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4502584 | 0.83 | GAA (0.58) | NR1H4GAAMAPTKMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4487996 | 0.83 | GAA (0.62) | NR1H4GAAMAPTKMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4490753 | 0.83 | GAA (0.57) | NR1H4GAAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL7975167 | 0.77 | GAA (0.70) | NR1H4GAAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4495325 | 0.76 | NR1H4 (0.66) | NR1H4TP53ATM | |
| Hydrochloric Acid SCHEMBL4495356 | 0.75 | NR1H4 (0.64) | NR1H4TP53ATM | |
| SCHEMBL5169503 | 0.74 | ATM (0.53) | NR1H4ATM | |
| SCHEMBL5165002 | 0.72 | GAA (0.59) | NR1H4GAAMAPTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592351-B2 | Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds | GRUENENTHAL GMBH (DE) | 2009-09-22 | — | — | US | claimed |
| US-20070099896-A1 | Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds | GRUENENTHAL GMBH (DE) | 2007-05-03 | — | — | US | claimed |
| EP-1756105-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND DRUGS CONTAINING SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2007-02-28 | — | — | EP | claimed |
| WO-2005105798-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND DRUGS CONTAINING SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2005-11-10 | — | — | WO | claimed |
| US-7592351-B2 | Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds | GRUENENTHAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20070099896-A1 | Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds | GRUENENTHAL GMBH (DE) | 2007-05-03 | — | — | US | disclosed |
| EP-1756105-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND DRUGS CONTAINING SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005105798-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND DRUGS CONTAINING SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099896-A1 | Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds | GIPR, CHUK, ITPA | NR1H4 2925/4885GAA 506/4885MAPT 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.